1012067-92-3

Basic information

• Product Name: Benzoic acid, 5-[(7-ethoxy-7-oxoheptyl)oxy]-4-methoxy-2-nitro-, ethyl ester
• CAS NO: 1012067-92-3
• Molecular Formula: C19H27NO8
• Molecular Weight: 397.425
• Mol File: 1012067-92-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 5-[(7-ethoxy-7-oxoheptyl)oxy]-4-methoxy-2-nitro-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-[(7-ethoxy-7-oxoheptyl)oxy]-4-methoxy-2-nitro-, ethyl ester(1012067-92-3)
• EPA Substance Registry System: Benzoic acid, 5-[(7-ethoxy-7-oxoheptyl)oxy]-4-methoxy-2-nitro-, ethyl ester(1012067-92-3)

Safety Data

• Hazardous Substances Data: 1012067-92-3(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 5-[(7-ethoxy-7-oxoheptyl)oxy]-4-methoxy-2-nitro-, ethyl ester is a chemical compound with the molecular formula C18H27NO7. It is an ethyl ester derivative of benzoic acid containing a nitro and methoxy group. This chemical is commonly used as a synthetic intermediate or building block in the production of various pharmaceuticals, agrochemicals, and other organic compounds. It is also used in the synthesis of bioactive molecules and as a reagent in organic chemistry reactions. However, it is important to handle and use this compound with caution due to its potential health hazards and environmental impacts.

Upstream product

• 148527-38-2 ethyl 3-hydroxy-4-methoxybenzoate 
• 3943-89-3 Ethyl protocatechuate 
• 29823-18-5 ethyl 7-bromoheptanoate 
• 1012057-22-5 ethyl 3-(7-ethoxy-7-oxoheptyloxy)-4-methoxybenzoate 

Downstream Products

• 1012067-93-4 ethyl 2-amino-5-(7-ethoxy-7-oxoheptyloxy)-4-methoxybenzoate 
• 1012057-21-4 ethyl 6-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)heptanoate 
• 1012054-99-7 N-(cyclohexanecarbonyloxy)-7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)heptanamide 
• 1012054-59-9 CUDC-101 

Relevant articles and documents

Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N- hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer

By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compounds with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N- hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clinical development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, respectively. In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib. In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. These results suggest that a single compound that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.

TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors.

QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

-